Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHK7791 (Tenapanor) + Phosphate Binders in Hyperphosphatemia on Hemodialysis
NCT03864445Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Apr 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hyperphosphatemia comparing KHK7791 + Binders with Placebo + Binders (2 arms). Primary endpoint: Change in serum phosphorus levels from baseline at 6 weeks. Started Apr 2019; status: completed.
02
Drugs
tenapanor
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT03864445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03864445.